Cardiff Oncology, Inc. (CRDF): who owns it and who trades it
As of Nov 16, 2026, CRDF insiders reported 4 purchases worth $1.1M in the last 12 months. The largest buyer was Gary W Pace (Director), with $1M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Cardiff Oncology
From the latest filingsOverall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CRDF
104 funds and institutions reported CRDF shares worth $24.3M at the end of Q2 2026, about 27% of the company. The largest holder is Laurion Capital Management LP with 4.5%.
Funds and institutions (13F) 27%Everyone else 73%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Laurion Capital Management LP | 3.10M | 4.53% | $4M | +17% |
| Vanguard Capital Management LLC | 2.90M | 4.24% | $3.8M | +1% |
| Pfizer Inc | 2.41M | 3.53% | $3M | No change |
| Franklin Resources Inc | 1.21M | 1.76% | $1.6M | No change |
| BlackRock, Inc. | 972,873 | 1.42% | $1.3M | -76% |
| Blair William & Co | 912,513 | 1.33% | $1.2M | -1% |
| Geode Capital Management, LLC | 820,062 | 1.20% | $1.1M | -49% |
| UBS Group AG | 638,699 | 0.93% | $830K | +59% |
| Jane Street Group, LLC | 607,900 | 0.89% | $790K | +1416% |
| Vanguard Fiduciary Trust Co | 410,602 | 0.60% | $534K | -8% |
| AQR Capital Management LLC | 346,353 | 0.51% | $450K | +424% |
| State Street Corp | 331,395 | 0.48% | $431K | -72% |
| Hrt Financial LP | 272,786 | 0.40% | $354K | – |
| Flputnam Investment Management Co | 247,474 | 0.36% | $322K | -58% |
| Morgan Stanley | 246,095 | 0.36% | $320K | +337% |
| BNP Paribas Financial Markets | 228,461 | 0.33% | $297K | +1647% |
| X-Square Capital, LLC | 205,700 | 0.30% | $267K | – |
| Gsa Capital Partners LLP | 173,274 | 0.25% | $225K | +41% |
| Marshall Wace, LLP | 162,214 | 0.24% | $211K | – |
| Bank of New York Mellon Corp | 161,689 | 0.24% | $210K | -47% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CRDF insiders reported $1.1M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | Gary W Pace | Director | Purchase | 687,285 | $1.46 | $1M | Form 4 |
| Jul 14, 2026 | Mani Mohindru | CEO | Purchase | 34,364 | $1.46 | $50.2K | Form 4 |
| Jun 18, 2026 | Mani Mohindru | CEO | Purchase | 24,703 | $1.21 | $29.9K | Form 4 |
| Jun 18, 2026 | Gary W Pace | Director | Purchase | 30,000 | $1.22 | $36.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Gary W Pace | Director | $1M | – | Jul 14, 2026 |
| Mani Mohindru | Chief Executive Officer, Director | $80.1K | – | Jul 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CRDF short interest
High short interest. 15.8% of CRDF shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 32%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 12.26M CRDF shares were sold short, 15.8% of the shares outstanding, up 1.2% from the report before. At the average daily volume of 397,871 shares, buying them all back would take about 30.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12.26M | 15.76% | +1% | 397,871 | 30.8 |
| Oct 15, 2026 | 12.12M | 15.58% | +0% | 433,441 | 28.0 |
| Sep 30, 2026 | 12.07M | 15.52% | -2% | 702,315 | 17.2 |
| Sep 15, 2026 | 12.31M | 15.82% | +5% | 1.02M | 12.1 |
| Aug 31, 2026 | 11.68M | 15.02% | -2% | 643,454 | 18.2 |
| Aug 14, 2026 | 11.90M | 15.29% | -2% | 778,972 | 15.3 |
| Jul 31, 2026 | 12.19M | 17.84% | +1% | 1.32M | 9.3 |
| Jul 15, 2026 | 12.09M | 17.68% | -6% | 1.96M | 6.2 |
| Jun 30, 2026 | 12.81M | 18.74% | -21% | 1.65M | 7.8 |
| Jun 15, 2026 | 16.15M | 23.62% | -11% | 2.03M | 8.0 |
| May 29, 2026 | 18.13M | 26.52% | +1% | 1.48M | 12.3 |
| May 15, 2026 | 18.02M | 26.35% | -2% | 670,314 | 26.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Cardiff Oncology company events
Cardiff Oncology filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Oct 27, 2026.
- Oct 27, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Oct 22, 2026VoteReported shareholder vote results. Filing
- Sep 14, 2026AgreementCardiff Oncology, Inc. and Nerviano Medical Sciences, S.r.l. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jul 16, 2026AgreementCardiff Oncology, Inc. entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to sell to such investors 8,571,429 shares of common stock of the Company and accompanying warrants to purchase up to 8,571,429 shares of Common Stock, at a… Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- Jun 3, 2026AnnouncementShared information with investors. Filing
- May 29, 2026AgreementAs previously disclosed, on May 19, 2026, Cardiff Oncology, Inc. filed a lawsuit against Nerviano Medical Sciences S.r.l. Filing
- May 19, 2026AnnouncementCardiff Oncology, Inc. filed a lawsuit against Nerviano Medical Sciences S.r.L disputing NMS’s allegation that the Company materially breached its license agreement (Agreement) for onvansertib. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Apr 9, 2026LeadershipCardiff Oncology, Inc. announced that Josh Muntner has been appointed the Company’s Chief Financial Officer effective April 6, 2026. Filing
- Apr 2, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Feb 25, 2026AnnouncementShared information with investors. Filing
- Feb 24, 2026DealCompleted a purchase or sale of a business or assets. Filing
- Jan 27, 2026LeadershipDr. Mark Erlander, Ph.D., CEO of Cardiff Oncology, Inc., and James Levine, CFO of the Company stepped down from their respective roles at the Company as part of a strategic leadership review. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Cardiff Oncology financials
Famous investors that hold CRDF
2 of the 50 well-known investors we track reported holding CRDF in their latest 13F filing. The largest position is Israel Englander's, worth $141K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 116,375 | $141K | 0.0% | -13% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 51,800 | $62.7K | 0.0% | +272% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CRDF in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Highbridge Capital Management, LLC | 13G | 5.8% |
| Nov 16, 2026 | Highbridge Capital Management, LLC | 13G | 5.8% |
Questions about Cardiff Oncology, Inc. (CRDF) stock
Who owns the most CRDF stock?
The largest reported owner of Cardiff Oncology, Inc. (CRDF) is Laurion Capital Management LP, with 4.5% of the company. In total, 104 funds and institutions reported holding CRDF at the end of Q2 2026, together about 27% of the shares. See the largest owners.
Are CRDF insiders buying or selling?
In the last 12 months, CRDF insiders reported 4 open-market purchases worth $1.1M and no sales. The latest trade was on Jul 14, 2026. See every trade.
What is the short interest in CRDF?
As of Oct 30, 2026, 12.26M CRDF shares were sold short, 15.8% of the shares outstanding, up 1.2% from the report before. At the average daily volume of 397,871 shares, buying them all back would take about 30.8 trading days (days to cover). See the history.
Which famous investors hold CRDF?
2 of the 50 well-known investors we track reported CRDF in their latest 13F filing, including Israel Englander, Jim Simons. The largest position is worth $141K. See all holders.
Executive pay
Cardiff Oncology's chief executive was paid a total of $3M for the year ended Dec 31, 2025, up 26% from $2.4M the year before. In the last 12 months, Cardiff Oncology's executives and directors bought $1.1M of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.